SavedAdd your journal

Journals / Selçuk Tıp Dergisi / 2021 / Cilt: 37 - Sayı: 2

Comparison of FDG PET/BT Findings and Neutrophil/ Lymphocyte Ratio in the Evaluation of the Extent of Sarcoidosis

Sarkoidozun Yaygınlığının Değerlendirilmesinde FDG PET/ BT Bulguları ile Nötrofil/Lenfosit Oranının Karşılaştırılması

Mustafa Erol
Hasan Önner
Pages
101–105
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There were strong correlations between NLR and whole body total lesion glycolysis (TLG), and moderate correlation between MAIA (r values: 0.852, 0.660, both of them p value:

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The decision of treatment in sarcoidosis is made based on clinical and radiological findings and changes in pulmonary function test findings during follow-up, and more useful tools are needed.
📊
Key Findings & Data:F-18 fluorodeoxyglucose (18F-FDG) positron required important tomography/computed tomography (PET/CT) contains information about the extent of sarcoidosis.
💡
Conclusion & Impact:There were strong correlations between NLR and whole body total lesion glycolysis (TLG), and moderate correlation between MAIA (r values: 0.852, 0.660, both of them p value:
🔬Design:Review & Systematic Survey
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Abstract

The decision of treatment in sarcoidosis is made based on clinical and radiological findings and changes in pulmonary function test findings during follow-up, and more useful tools are needed. F-18 fluorodeoxyglucose (18F-FDG) positron required important tomography/computed tomography (PET/CT) contains information about the extent of sarcoidosis. Neutrophil/lymphocyte ratio (NLR) opens as a prognostic marker for inflammation. This study evaluated the relationship between the 18F-FDG PET/CT findings of sarcoidosis and NLR and other clinical findings. Patients and Methods: The data of patients who were diagnosed with sarcoidosis after 18F-FDG PET/ CT scan in our clinic between January 2017 and December 2019 were reviewed retrospectively. Patients' age, gender, NLR values, smoking status, extrathoracic involvement and symptoms, and 18F-FDG PET/CT findings were compared. Results: This study consisted of 41 patients. There were strong correlations between NLR and whole body total lesion glycolysis (TLG), and moderate correlation between MAIA (r values: 0.852, 0.660, both of them p value:

Özet

Amaç: Sarkoidoz tedavisinin kararında, klinik ve radyolojik bulgular ile takipte solunum fonksiyon testindeki bozulmaya bakılmakta olup, tedavi yönetiminde farklı tetkiklere ihtiyaç duyulmaktadır. Flor-18 florodeoksiglukoz (18F-FDG) pozitron emisyon tomografisi/bilgisayarlı tomografi (PET/BT) hastalığın yaygınlığı hakkında bilgi verirken; nötrofil/lenfosit oranı (NLO) inflamasyon için iyi bir prognostik belirteç olarak bildirilmektedir. Bu çalışmada, sarkoidozun 18F-FDG PET/BT bulguları ile NLO ve diğer klinik bulgular arasındaki ilişkiyi . Hastalar ve Yöntem: Ocak 2017 - Aralık 2019 tarihleri arasında Kliniğimizde, 18F-FDG PET/BT tetkiki sarkoidoz tanısı alan hastaların verileri NLO ve retrospektif olarak tarandı. Yaş, cinsiyet, sigara öyküsü, semptomlar, ekstratorasik tutulum varlığı ile 18F-FDG PET/BT bulguları karşılaştırıldı. Bulgular: Çalışmaya 41 hasta dahil edildi. NLO ile tüm vücut toplam lezyon glikolizi (TLG) arasında güçlü, tüm vücut metabolik aktif inflamatuar alan (MAİA) arasında orta düzeyde anlamlı korelasyon saptandı (Sırasıyla r değerleri: 0.852, 0.660; her ikisi içinde p değeri:

🔖

Cite This Article

Erol, M., Önner, H. (2022). Comparison of FDG PET/BT Findings and Neutrophil/ Lymphocyte Ratio in the Evaluation of the Extent of Sarcoidosis. Selçuk Tıp Dergisi, Cilt: 37 - Sayı: 2, 101–105. https://ajindex.com/articles/591781

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Hutchinson J. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ER. Am J Respir Crit Care Med 1999;160(736):55. Musellim B, Kumbasar O, Ongen G, et al. Epidemiological features of Turkish patients with sarcoidosis. Respir Med 2009;103(6):907-12.
  2. Soto-Gomez N, Peters JI, Nambiar AM. Diagnosis and management of sarcoidosis. Am Fam Physician 2016;93(10):840-8.
  3. Spagnolo P, Rossi G, Trisolini R, et al. Pulmonary sarcoidosis. Lancet Respir Med 2018;6(5):389-402.
  4. Papiris SA, Manali ED, Pianou NK, et al. 18F-FDG PET/CT in pulmonary sarcoidosis: Quantifying inflammation by the TLG index. Expert Rev Respir Med 2020;14(1):103-10.
  5. Wetzel E, Müller-Quernheim J, Lorenz J. Serum adenosine deaminase as a parameter for activity in sarcoidosis. Pneumologie 1999;53(7):323-8.
  6. Gungor S, Ozseker F, Yalcinsoy M, et al. Conventional markers in determination of activity of sarcoidosis. Int Immunopharmacol 2015;25(1):174-9.
  7. Gungor S, Akturk U, Yalcinsoy M, et al. What is the neutrophil/ lymphocyte ratio in sarcoidosis? Bratisl Lek Listy 2016;152- 5. Iliaz S, Iliaz R, Ortakoylu G, et al. Value of neutrophil/ lymphocyte ratio in the differential diagnosis of sarcoidosis and tuberculosis. Ann Thorac Med 2014;9(4):232. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33(11):1972-80. 11. Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001;42(10):1551-5.
  8. Jamar F, Buscombe J, Chiti A, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med 2013;54(4):647-58.
  9. Hunninghake G, Costabel U, Ando M, et al. ATS/ERS/ WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999;16(2):149. Judson MA. Sarcoidosis: Clinical presentation, diagnosis, and approach to treatment. Am J Med Sci 2008;335(1):26- 33. Agostini C, Semenzato G, editors. Cytokines in sarcoidosis. Semin Respir Infect 1998;13(3):184-96.
  10. Sweiss NJ, Salloum R, Ghandi S, et al. Significant CD4, CD8, and CD19 lymp